PDF Cover

Lanadelumab Market

The market for Lanadelumab was estimated at $628 million in 2024; it is anticipated to increase to $1.08 billion by 2030, with projections indicating growth to around $1.70 billion by 2035.

Report ID:DS1802285
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Lanadelumab
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Lanadelumab Market Outlook

Revenue, 2024

$628M

Forecast, 2034

$1.56B

CAGR, 2025 - 2034

9.5%

The Lanadelumab industry revenue is expected to be around $687.1 million in 2025 and expected to showcase growth with 9.5% CAGR between 2025 and 2034. Following this growth trajectory, Lanadelumab has become an essential biologic therapy in the long-term prevention of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent and potentially life-threatening swelling episodes. Increasing diagnosis rates, improved access to rare disease treatments, and growing awareness among immunologists and allergy specialists are strengthening market demand. The therapy’s ability to significantly reduce attack frequency with a convenient dosing schedule has positioned it as a preferred prophylactic option in many treatment guidelines. Continued expansion of reimbursement coverage, orphan drug incentives, and investments in rare disease management are further reinforcing Lanadelumab’s clinical and commercial importance across major pharmaceutical markets.

Lanadelumab is a fully human monoclonal antibody that selectively inhibits plasma kallikrein, a key enzyme involved in excessive bradykinin production that triggers hereditary angioedema attacks. Marketed as Takhzyro by Takeda Pharmaceutical Company, it is administered as a subcutaneous injection and is primarily indicated for routine prevention of HAE attacks in patients aged 2 years and older in many markets. Its targeted mechanism, sustained efficacy, and reduced dosing frequency offer substantial advantages over older prophylactic therapies requiring more frequent administration. Major applications are centered on hospital specialty pharmacies, rare disease clinics, and home-based self-administration programs. Recent trends driving demand include earlier initiation of prophylactic therapy, pediatric label expansions, patient support services, and ongoing research into personalized treatment strategies for complement and kallikrein-mediated disorders.

Lanadelumab market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Lanadelumab Market Outlook

Market Key Insights

  • The Lanadelumab market is projected to grow from $627.5 million in 2024 to $1.56 billion in 2034. This represents a CAGR of 9.5%, reflecting rising demand across Hereditary Angioedema Prophylaxis, High-Risk Patient Treatment, and Biopharmaceutical Research.

  • Takeda Pharmaceuticals is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Lanadelumab market and are expected to observe the growth CAGR of 6.9% to 10.0% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 9.1% to 11.9%.

  • Slow adoption of Hereditary Angioedema Care Transitions from Acute Rescue Treatment to Preventive Biologic Therapy transition within key players in Lanadelumab market is creating a revenue window for adjacent and alternate markets like Orladeyo and C1 Inhibitor Replacement Therapies to improve its use-case penetration in HAE Type I and HAE Type II applications and expected to capture $58 million revenue from existing Lanadelumab market.

  • The Lanadelumab market is set to add $928 million between 2024 and 2034, with manufacturer targeting Homecare & Specialty Centers Application projected to gain a larger market share.

  • With

    increasing incidence of hereditary angioedema, and

    Breakthroughs in Therapeutic Technology, Lanadelumab market to expand 148% between 2024 and 2034.

lanadelumab market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Lanadelumab - Country Share Analysis

Opportunities in the Lanadelumab

The pediatric segment represents a high-value opportunity as clinicians increasingly favor preventive treatment rather than reactive management of hereditary angioedema. Lanadelumab’s subcutaneous administration and durable plasma kallikrein inhibition make it well suited for children requiring consistent attack prevention and improved quality of life. Growing caregiver demand for home-based treatment and reduced hospitalization is also accelerating uptake. The strongest expansion is expected in self-administered formulations supplied through specialty pharmacies in North America and Europe, where clinical guidelines and reimbursement systems increasingly support early initiation of biologic prophylaxis in younger patient populations.

Growth Opportunities in North America and Europe

The market for Lanadelumab is experiencing growth in North America due to a rising need for effective treatments for hereditary angioedema. The region has healthcare facilities especially in the United States that are driving innovative research in new medications like Lanadelumab. The flourishing pharmaceutical sector in America plays a role in boosting the market for Lanadelumab along with substantial investments, in medical research and development efforts. North America's advanced adoption of Lanadelumab for treating angioedema is evident through the crowded market and fierce competition it faces in the regions mature market landscape. The factors driving this market include advancements in bioengineering technology increased spending, on healthcare and growing awareness of genetic conditions.
In Europe at the time there are encouraging opportunities for researching Lanadelumab due to a changing healthcare approach that emphasizes personalized medicine. Leading the way in the use of Lanadelumab are the United Kingdom, Germany and France supported by a pharmaceutical sector that enables the development of new treatments. Significantly the competitive situation for Lanadelumab, in Europe is influenced by market participants who are driving progress in treating hereditary angioedema. The main factors influencing this region are the increasing cases of angioedema and strong healthcare regulations and increased healthcare expenditures.

Market Dynamics and Supply Chain

01

Driver: Increasing hereditary angioedema diagnosis and growing preference for targeted biologic therapies

The lanadelumab market is also driven by the rising diagnosis rate of hereditary angioedema and the growing clinical preference for targeted biologic therapies. Improved genetic screening, wider clinical awareness, and expanded diagnostic protocols have also increased identification of HAE patients who require long-term management, enlarging the addressable patient population. Parallel to this, clinicians and patients are also increasingly adopting monoclonal antibody therapies like lanadelumab due to their specificity, sustained efficacy, and reduced attack rates compared with older treatments. also advances in biologic development have also improved safety profiles and extended dosing intervals, enhancing patient adherence and quality of life. These factors collectively encourage healthcare providers to shift toward precision biologics for prophylaxis, supporting robust market demand and reinforcing lanadelumab’s role as a first-line preventive option in specialized immunology and rare disease care.
A key trend driving the lanadelumab market is also the expansion of patient-centric delivery models, including home administration and user-friendly injection platforms. Lanadelumab’s subcutaneous formulation enables self-administration or caregiver administration outside clinical settings, reducing the burden of frequent hospital visits and improving convenience. This trend resonates with broader healthcare shifts toward decentralized care and chronic disease management at home. Easier delivery fosters better adherence to prophylactic regimens, translating to sustained therapeutic outcomes and reduced emergency interventions. The resulting improvement in patient experience and healthcare resource utilization supports broader uptake among HAE patients globally.
02

Restraint: High treatment costs and limited insurance reimbursement constrain lanadelumab adoption

A major restraint on the lanadelumab market is its high cost relative to alternative therapies, which limits access and uptake, especially in markets with restricted insurance coverage. As a biologic therapy for hereditary angioedema prophylaxis, lanadelumab can carry substantial per-dose pricing, and patients may face significant out-of-pocket expense when reimbursement is inadequate. For example, in certain emerging economies or private pay settings, budget-constrained healthcare providers may prioritize cheaper alternatives or delay adoption, reducing overall demand. This cost sensitivity can slow revenue growth for manufacturers and restrict long-term treatment consistency among diagnosed patients.
03

Opportunity: Emerging Asian Rare Disease Centers Expand Prophylactic HAE Treatment Access and Middle Eastern Specialty Clinics Increase Demand for Orphan Biologic Therapies

Asia-Pacific presents a substantial opportunity for lanadelumab as hereditary angioedema diagnosis and rare disease infrastructure improve across Japan, China, South Korea, and select Southeast Asian markets. Historically underdiagnosed patient populations are gaining access to specialist immunology centers, genetic testing, and reimbursement pathways. Strategic collaborations between rare disease advocacy groups, healthcare providers, and pharmaceutical companies are increasing awareness of long-term prophylaxis. The greatest growth is expected in hospital and specialty pharmacy distribution channels, with Asia-Pacific projected to be the fastest-expanding regional market as governments strengthen orphan drug policies and expand coverage for advanced biologic therapies.
The Middle East is emerging as a niche opportunity for lanadelumab due to expanding investment in tertiary care centers and rare disease treatment programs. Countries such as Saudi Arabia and the United Arab Emirates are improving access to genetic diagnostics and high-cost biologics through centralized procurement and government-funded healthcare systems. Partnerships between global pharmaceutical companies and regional distributors are strengthening product availability. Hospital-based administration and specialty pharmacy channels are expected to grow most rapidly as awareness of hereditary angioedema improves and clinicians adopt targeted monoclonal antibody therapies for long-term attack prevention.
04

Challenge: Competition from alternative therapies and emerging treatment modalities reduces market share

Another key restraint is increasing competition from alternative therapies, including oral prophylactics like berotralstat and other biologics or C1-inhibitors that challenge lanadelumab’s market position. As clinicians adopt newer or more convenient options, prescribing patterns may shift away from lanadelumab, eroding its share in HAE management. For instance, broader use of C1-esterase inhibitors for both acute and prophylactic use can diminish lanadelumab’s exclusivity in certain patient subgroups. This competitive environment creates pricing pressure and necessitates continued investment in differentiation, potentially slowing revenue expansion and altering demand behavior.

Supply Chain Landscape

1

Biologic API Production

Lonza GroupWuXi Biologics
2

Drug Substance Processing

Takeda PharmaceuticalsLonza Group
3

Fill–Finish Manufacturing

Takeda Pharmaceuticals
4

Distribution & End Users

Pharmacy ChainsHospitalsSpecialty Clinics
Lanadelumab - Supply Chain

Use Cases of Lanadelumab in Hereditary Angioedema Prophylaxis & Biopharmaceutical Research

Hereditary Angioedema Prophylaxis : Lanadelumab is predominantly used as a long-term prophylactic therapy for patients with hereditary angioedema to prevent recurrent and unpredictable swelling attacks. Administered as a subcutaneous monoclonal antibody injection, it works by selectively inhibiting plasma kallikrein, thereby reducing bradykinin production that triggers edema. This targeted mechanism offers sustained attack prevention with dosing every two to four weeks, improving treatment adherence. Its high efficacy in reducing attack frequency makes lanadelumab a preferred option for patients requiring consistent, preventive management rather than on-demand therapy, supporting better quality of life and reduced emergency care dependence.
High-Risk Patient Treatment : In high-risk patient treatment, lanadelumab is mainly prescribed for individuals experiencing frequent, severe, or life-threatening hereditary angioedema attacks, including those with prior airway involvement. The injectable monoclonal antibody formulation provides stable kallikrein inhibition, offering reliable protection for patients with poor response or intolerance to older prophylactic options. Its predictable pharmacokinetic profile allows clinicians to tailor dosing intervals based on patient risk levels. This application is particularly valuable in specialized allergy and immunology clinics, where reducing hospitalization risk, work disruption, and psychological stress associated with severe HAE attacks is a key therapeutic objective.
Biopharmaceutical Research : Lanadelumab also plays an important role in biopharmaceutical research focused on rare diseases and targeted antibody therapies. In this application, it is primarily used as a reference monoclonal antibody to study plasma kallikrein inhibition and bradykinin pathway modulation. Researchers leverage lanadelumab to evaluate long-acting biologic design, dosing optimization, and real-world effectiveness in rare disease populations. Its success has encouraged further investment in monoclonal antibody platforms and precision therapies, influencing broader research efforts in inflammatory and complement-mediated disorders and advancing innovation across the rare disease biopharmaceutical landscape.

Impact of Industry Transitions on the Lanadelumab Market

As a core segment of the Pharmaceutical industry, the Lanadelumab market develops in line with broader industry shifts. Over recent years, transitions such as Hereditary Angioedema Care Transitions from Acute Rescue Treatment to Preventive Biologic Therapy and Rare Disease Commercial Models Shift Toward Home-Based Specialty Pharmacy Distribution have redefined priorities across the Pharmaceutical sector, influencing how the Lanadelumab market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Hereditary Angioedema Care Transitions from Acute Rescue Treatment to Preventive Biologic Therapy

The lanadelumab market reflects a major shift in hereditary angioedema management from treating attacks after onset to preventing them through long-term prophylaxis. Healthcare providers and payers increasingly favor therapies that reduce emergency visits, hospitalizations, and productivity losses. Takhzyro has accelerated this transition by offering durable attack prevention through convenient subcutaneous dosing. For example, specialty clinics are moving eligible patients from on-demand C1 esterase inhibitors to routine prophylaxis, creating more predictable prescription volumes for specialty pharmacies and improving outcomes. This shift is expanding the role of rare disease biologics and increasing strategic investment in preventive immunology therapies.
02

Rare Disease Commercial Models Shift Toward Home-Based Specialty Pharmacy Distribution

The lanadelumab industry is also transitioning from hospital-centered administration to patient-centric distribution through specialty pharmacies and home care programs. Manufacturers and healthcare providers are emphasizing reimbursement support, nurse education, and adherence services to strengthen long-term treatment persistence. This model reduces dependence on infusion centers and improves convenience for patients and caregivers. For instance, payers in North America and Europe increasingly reimburse self-administered biologics delivered directly to patients, supporting higher retention rates and broader access. The transition is reshaping competition around patient support infrastructure, market access capabilities, and real-world evidence rather than solely on clinical efficacy.